058820 — CMG Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00- KR₩277bn
- KR₩323bn
- KR₩105bn
Annual balance sheet for CMG Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 90,341 | 77,813 | 68,827 | 76,794 | 26,410 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 21,016 | 34,705 | 24,633 | 32,524 | 35,360 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 125,482 | 135,070 | 115,737 | 134,859 | 95,179 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 30,516 | 37,472 | 50,711 | 77,977 | 114,994 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 199,175 | 213,260 | 242,098 | 303,437 | 305,962 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13,729 | 21,903 | 24,529 | 74,645 | 103,656 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 14,472 | 28,307 | 51,866 | 113,895 | 104,407 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 184,702 | 184,953 | 190,233 | 189,542 | 201,555 |
| Total Liabilities & Shareholders' Equity | 199,175 | 213,260 | 242,098 | 303,437 | 305,962 |
| Total Common Shares Outstanding |